TD-HX139026

Melrilimab(TD-HX139026) is a research-grade recombinant antibody targetingT1. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Human

IgG2-Kappa

Monoclonal

T1, DER4, Interleukin-1 receptor-like 1, ST2, IL1RL1, Protein ST2

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

Q01638

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

3772847-A, CNTO-7160, GSK-3772847, GSK-3772847-A, 2222865-46-3

Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. Astegolimab has the potential for chronic obstructive pulmonary disease (COPD) research.• T1/ST2--an IL-1 receptor-like modulator of immune responses., PMID:15110792• The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors., PMID:9794420• Identification of the primary growth response gene, ST2/T1, as a gene whose expression is differentially regulated by different protein kinase C isozymes., PMID:7556667

SDS-PAGE for Research Grade Melrilimab

For research use only. Not suitable for clinical or therapeutic use.